Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest Migraine With Aura Stories

2008-10-24 15:00:24

ESSEX, United Kingdom, Oct. 24 /PRNewswire-FirstCall/ -- Minster Pharmaceuticals plc (AIM: MPM), the drug development company specializing in neurological and psychiatric disorders, is pleased to announce positive results from its Phase II trial in Denmark of tonabersat in the prevention of migraine with aura. The median number of aura attacks was reduced by 68% (p=0.01) in patients receiving tonabersat when compared with placebo. This result in the primary endpoint of the study is both...

2008-09-05 09:00:38

NeurAxon, Inc., a developer of next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), today announced data from its Phase 2 clinical trial of NXN-188 in patients with migraine. In the study, patients experiencing migraine with aura, which represents over 7 million patients in the US, achieved sustained relief from their headaches, representing a potentially differentiated treatment profile from current migraine therapies. These data were presented in a session at...